MAC
53
5
CNX
67
4
MA
60
5
MTCH
62
22
UNH
42
6
AIG
38
5
KHC
11
2
HPE
48
2
CAT
47
3
DGX
28
4
SRE
37
9
HCA
37
7
OXY
42
17
PEP
33
4
AAPL
64
3
CMCSA
49
3
EXPE
83
8
CCL
68
6
JWN
72
9
EW
55
5
MAC
53
5
CNX
67
4
MA
60
5
MTCH
62
22
UNH
42
6
AIG
38
5
KHC
11
2
HPE
48
2
CAT
47
3
DGX
28
4
SRE
37
9
HCA
37
7
OXY
42
17
PEP
33
4
AAPL
64
3
CMCSA
49
3
EXPE
83
8
CCL
68
6
JWN
72
9
EW
55
5
Financhill
Back

Novo Nordisk AS Quote, Financials, Valuation and Earnings

Trump's Legacy-Defining Momentor Strike

But the Surprising Way Trump Solves it Could Cement His Legacy.
Sell
23

NVO
Novo Nordisk AS

Last Price:
$85.00
Seasonality Move:
6.92%

7 Day Trial

ALL ACCESS PASS

$ 7

2025 Gold Forecast: A Perfect Storm for Demand

Discover our Gold Price Outlook for 2025--FREE--here

Novo Nordisk AS Price Quote

$85.00

Novo Nordisk AS Key Stats

Sell
23
Novo Nordisk AS (NVO) is a Sell
Day range:
$81.50 - $86.53
52-week range:
$81.50 - $148.15
Dividend yield:
1.7%
P/E ratio:
31.44
P/S ratio:
9.65
P/B ratio:
20.91%
Volume:
53.4M
Avg. volume:
6.9M
1-year change:
-16.1%
Market cap:
$377.5B
Revenue:
$33.7B
EPS:
$3.09

How Much Does Novo Nordisk AS Make?

Data Unavailable

Is Novo Nordisk AS Growing As A Company?

Data Unavailable

Novo Nordisk AS Stock Price Performance

  • Did Novo Nordisk AS Stock Go Up Last Month?
    Novo Nordisk AS share price went down by -19.26% last month
  • Did NVO's Share Price Rise Over The Last Year?
    NVO share price fell by -16.1% over the past 1 year

What Is Novo Nordisk AS 52-Week High & Low?

Novo Nordisk AS Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Novo Nordisk AS?

Data Unavailable

Is Novo Nordisk AS Cash Flow Positive?

Data Unavailable

Novo Nordisk AS Return On Invested Capital

Data Unavailable

Novo Nordisk AS Earnings Date & Stock Price

Novo Nordisk AS Competitors

  • Who Are Novo Nordisk AS's Competitors?
    Below is a list of companies who compete with Novo Nordisk AS or are related in some way:
    • Akari Therapeutics PLC (AKTX)
    • Amgen Inc (AMGN)
    • Ascendis Pharma AS (ASND)
    • Evaxion Biotech AS (EVAX)
    • Viking Therapeutics Inc (VKTX)

Novo Nordisk AS Dividend Yield

Data Unavailable

Novo Nordisk AS Analyst Estimates

YoY Growth Past Surprise
EPS: 23.52% 3.93%
Revenue: 22.53% -0.31%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 2
Sell Recommendations: 1
Price Target: 122.11
Upside from Last Price: 43.66%

Major Shareholders

Data Unavailable